Technical Analysis for ZSAN - Zosano Pharma Corporation

Grade Last Price % Change Price Change
grade F 2.763 3.10% 0.08
ZSAN closed down 4.29 percent on Tuesday, May 21, 2019, on 82 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ZSAN trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 3.10%
Wide Bands Range Expansion 3.10%
Below Lower BB Weakness 3.10%
Down 3 Days in a Row Weakness 3.10%
Down 4 Days in a Row Weakness 3.10%
Down 5 Days in a Row Weakness 3.10%
Lower Bollinger Band Touch Weakness 3.10%
Oversold Stochastic Weakness 3.10%
Lower Bollinger Band Walk Weakness -1.32%
Wide Bands Range Expansion -1.32%

Older signals for ZSAN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Zosano Pharma Corporation, a clinical stage specialty pharmaceutical company, develops drug formulations for the treatment of various indications. The company delivers formulations through the skin using its proprietary transdermal microneedle patch system. Its lead product candidates comprise Weekly ZP-PTH, a proprietary formulation of parathyroid hormone that has completed a Phase I clinical study for the treatment of severe osteoporosis in women; ZP-Glucagon, a proprietary formulation of glucagon, which has completed a Phase I study for the emergency treatment of severe hypoglycemia; and ZP-Triptan, a proprietary formulation of zolmitriptan that has completed preclinical animal studies for the treatment of migraine. Zosano Pharma Corporation has a strategic partnership and license agreement with Novo Nordisk A/S to develop a microneedle patch product to administer semaglutide for the treatment of type 2 diabetes. The company was founded in 2006 and is headquartered in Fremont, California.
Diabetes Migraine Stage Specialty Pharmaceutical Treatment Of Migraine Emergency Treatment Severe Hypoglycemia Triptans
Is ZSAN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.65
52 Week Low 1.85
Average Volume 714,242
200-Day Moving Average 3.6921
50-Day Moving Average 4.0548
20-Day Moving Average 3.467
10-Day Moving Average 3.169
Average True Range 0.2736
ADX 20.33
+DI 12.2305
-DI 28.9772
Chandelier Exit (Long, 3 ATRs ) 3.3292
Chandelier Exit (Short, 3 ATRs ) 3.4608
Upper Bollinger Band 4.2118
Lower Bollinger Band 2.7222
Percent B (%b) -0.03
BandWidth 42.9651
MACD Line -0.3016
MACD Signal Line -0.2396
MACD Histogram -0.062
Fundamentals Value
Market Cap 105.12 Million
Num Shares 39.2 Million
EPS -1.28
Price-to-Earnings (P/E) Ratio -2.09
Price-to-Sales 0.00
Price-to-Book 1.29
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.06
Resistance 3 (R3) 3.09 2.99 3.00
Resistance 2 (R2) 2.99 2.90 2.98 2.98
Resistance 1 (R1) 2.84 2.84 2.79 2.81 2.96
Pivot Point 2.74 2.74 2.71 2.72 2.74
Support 1 (S1) 2.58 2.64 2.53 2.55 2.40
Support 2 (S2) 2.48 2.58 2.47 2.38
Support 3 (S3) 2.33 2.48 2.36
Support 4 (S4) 2.30